- Home
- SATL vs OPTN Comparison
SATL vs OPTN Comparison
Compare SATL & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- OPTN
- Stock Information
- Founded
- SATL 2010
- OPTN 2010
- Country
- SATL Uruguay
- OPTN United States
- Employees
- SATL N/A
- OPTN N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- OPTN Health Care
- Exchange
- SATL Nasdaq
- OPTN Nasdaq
- Market Cap
- SATL 95.7M
- OPTN 99.7M
- IPO Year
- SATL N/A
- OPTN 2017
- Fundamental
- Price
- SATL $1.25
- OPTN $0.40
- Analyst Decision
- SATL
- OPTN Strong Buy
- Analyst Count
- SATL 0
- OPTN 3
- Target Price
- SATL N/A
- OPTN $3.00
- AVG Volume (30 Days)
- SATL 100.2K
- OPTN 1.1M
- Earning Date
- SATL 12-03-2024
- OPTN 11-12-2024
- Dividend Yield
- SATL N/A
- OPTN N/A
- EPS Growth
- SATL N/A
- OPTN N/A
- EPS
- SATL N/A
- OPTN N/A
- Revenue
- SATL $13,719,000.00
- OPTN $75,672,000.00
- Revenue This Year
- SATL N/A
- OPTN $24.44
- Revenue Next Year
- SATL N/A
- OPTN $49.00
- P/E Ratio
- SATL N/A
- OPTN N/A
- Revenue Growth
- SATL 101.51
- OPTN 5.13
- 52 Week Low
- SATL $0.72
- OPTN $0.32
- 52 Week High
- SATL $2.52
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- SATL 72.03
- OPTN 28.41
- Support Level
- SATL $0.93
- OPTN $0.32
- Resistance Level
- SATL $1.09
- OPTN $0.46
- Average True Range (ATR)
- SATL 0.07
- OPTN 0.07
- MACD
- SATL 0.03
- OPTN -0.03
- Stochastic Oscillator
- SATL 82.95
- OPTN 15.45
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.